tert-butyl N-[(E)-C-methyl-N-(trifluoromethylsulfonyl)carbonimidoyl]carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: tert-butyl N-[(E)-C-methyl-N-(trifluoromethylsulfonyl)carbonimidoyl]carbamate
• 化学式: C₈H₁₃F₃N₂O₄S
• 分子量: 290.26
• InChiKey: XQPWCWFPKBCWHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  93.2
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• LYSINE OLIGOMER DERIVATIVE AND CARTILAGE TISSUE MARKER MADE THEREOF
  申请人：NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY

  公开号：US20150080551A1

  公开（公告）日：2015-03-19

  There is provided a lysine oligomer derivative, wherein an ε-amino group and a carboxyl group of lysines are linked via a peptide bond, and a group capable of generating or absorbing electromagnetic wave is bonded to a C-terminal carboxyl group, an N-terminal amino group and/or an α-amino group. This lysine oligomer derivative has the characteristic of specifically accumulating in the cartilage matrix and can generate or absorb an electromagnetic wave, and is, therefore, useful as a cartilage tissue marker.

  提供一种赖氨酸寡聚物衍生物，其中赖氨酸的ε-氨基团和羧基通过肽键连接，并且能够产生或吸收电磁波的基团与C-末端羧基、N-末端氨基和/或α-氨基结合。这种赖氨酸寡聚物衍生物具有特异性积聚在软骨基质中的特性，可以产生或吸收电磁波，因此可作为软骨组织标记物。
• STABLE SODIUM CHANNEL BLOCKERS
  申请人：PARION SCIENCES, INC.

  公开号：US20150376145A1

  公开（公告）日：2015-12-31

  A very stable, selective and renally safe sodium channel blocker represented by the formula: The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.

  一种由以下式子代表的非常稳定、选择性和肾脏安全的钠通道阻滞剂：该发明还包括使用这种创新的钠通道阻滞剂的各种组合、组合和治疗方法。
• MEXILETINE PRODRUGS
  申请人：Franklin Richard

  公开号：US20120196933A1

  公开（公告）日：2012-08-02

  The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided.

  本发明涉及美西律定（以及美西律定的活性代谢物）的前药以及含有这些前药的药物组合物。还提供了治疗肌张力不良症的方法，同时减少与美西律定相关的固有不良胃肠副作用，增加美西律定的生物利用度，并改善美西律定的药代动力学可重复性。
• HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS
  申请人：JOHNSON Michael Ross

  公开号：US20120116083A1

  公开（公告）日：2012-05-10

  Polyaromatic sodium channel blockers represented by the formula: are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.

  本发明提供了由以下式子所代表的多环芳香基钠通道阻滞剂，其中结构变量在此定义。本发明还包括使用这些创新的钠通道阻滞剂的各种组合、组成物和治疗方法。
• POLY AROMATIC SODIUM CHANNEL BLOCKERS
  申请人：JOHNSON Michael Ross

  公开号：US20140031371A1

  公开（公告）日：2014-01-30

  Polyaromatic sodium channel blockers represented by the formula: are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.

  本发明提供了由以下公式表示的多环芳香族钠通道阻滞剂，其中结构变量在此定义。本发明还包括使用这些创新的钠通道阻滞剂的各种组合和治疗方法。